Amarin Will Double Vascepa Sales Team In Big Bet On Supplemental Approval
Executive Summary
Anticipating a label expansion this fall based on the REDUCE-IT cardiovascular outcomes study, Amarin will double its sales force and has raised revenue guidance. Approved to reduce very high triglyceride levels, Vascepa sales total $170m-$174m so far this year.
You may also be interested in...
Amarin’s Q1 Vascepa Sales Exceed Expectations, But Uncertainties Remain
First quarter revenue of $150m beat analyst consensus of $129m, but investors remain wary of Amarin’s ability to overturn its recent Vascepa patent defeat and execute a favorable European strategy.
Keeping Track: A Busy Week For Regenerative Medicine, A Surprise Priority Review For Vascepa, And Tazemetostat Aims For Accelerated Approval
The latest drug development news and highlights from our US FDA Performance Tracker.
Amarin's Vascepa Gets ADA Recommendation For Patients With Diabetes And High Triglycerides
The company has racked up a lot of wins for its proprietary fish oil derivative based on the REDUCE-IT study, the latest being inclusion in diabetes treatment guidelines. Amarin also has now submitted a supplemental NDA seeking a label update reflecting the outcomes trial results.